{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:04:28Z","timestamp":1792598668368,"version":"4.5.0"},"reference-count":122,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T00:00:00Z","timestamp":1465948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In recent years, immune checkpoint inhibitors have emerged as effective therapies for advanced neoplasias. As new checkpoint target blockers become available and additional tumor locations tested, their use is expected to increase within a short time. Immune-related adverse events (irAEs) affecting the endocrine system are among the most frequent and complex toxicities. Some may be life-threatening if not recognized; hence, appropriate guidance for oncologists is needed. Despite their high incidence, endocrine irAEs have not been fully described for all immunotherapy agents available. This article is a narrative review of endocrinopathies associated with cytotoxic T lymphocyte-associated antigen-4, blockade of programmed death receptor 1 and its ligand inhibitors, and their combination. Thyroid dysfunction is the most frequent irAE reported, and hypophysitis is characteristic of ipilimumab. Incidence, timing patterns, and clinical presentation are discussed, and practical recommendations for clinical management are suggested. Heterogeneous terminology and lack of appropriate resolution criteria in clinical trials make adequate evaluation of endocrine AEs difficult. It is necessary to standardize definitions to contrast incidences and characterize toxicity patterns. To provide optimal care, a multidisciplinary team that includes endocrinology specialists is recommended.<\/jats:p>","DOI":"10.1634\/theoncologist.2015-0509","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T05:49:20Z","timestamp":1466056160000},"page":"804-816","source":"Crossref","is-referenced-by-count":223,"title":["Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events"],"prefix":"10.1093","volume":"21","author":[{"given":"Elisa","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Section of Endocrinology and Nutrition, Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys","family":"Rodr\u00edguez-Abreu","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,15]]},"reference":[{"key":"2021122309534650500_B1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/COC.0b013e318209cda9","article-title":"Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses?","volume":"35","author":"Pennock","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"2021122309534650500_B2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"2021122309534650500_B3","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","article-title":"CTLA-4 ligation blocks CD28-dependent T cell activation","volume":"183","author":"Walunas","year":"1996","journal-title":"J Exp Med"},{"key":"2021122309534650500_B4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122309534650500_B5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122309534650500_B6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.seminoncol.2010.09.004","article-title":"Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade","volume":"37","author":"Boasberg","year":"2010","journal-title":"Semin Oncol"},{"key":"2021122309534650500_B7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-9966-33-30","article-title":"Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme","volume":"33","author":"Chiarion Sileni","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"2021122309534650500_B8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122309534650500_B9","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122309534650500_B10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B11","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"2021122309534650500_B12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"2021122309534650500_B13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"2021122309534650500_B14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2021122309534650500_B15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J Immunother"},{"key":"2021122309534650500_B16","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B17","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2021122309534650500_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2021122309534650500_B20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4158\/EP11273.OR","article-title":"Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series","volume":"18","author":"Min","year":"2012","journal-title":"Endocr Pract"},{"key":"2021122309534650500_B21","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1152\/ajpendo.00434.2002","article-title":"The melanocortin system","volume":"284","author":"Gantz","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2021122309534650500_B22","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/1078-0432.CCR-08-2424","article-title":"Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4","volume":"15","author":"Klein","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122309534650500_B23","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13277-014-2784-1","article-title":"Positive expression of pro-opiomelanocortin (POMC) is a novel independent poor prognostic marker in surgically resected non-small cell lung cancer","volume":"36","author":"Hao","year":"2015","journal-title":"Tumour Biol"},{"key":"2021122309534650500_B24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122309534650500_B25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00262-010-0958-2","article-title":"Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)","volume":"60","author":"Di Giacomo","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"2021122309534650500_B26","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"key":"2021122309534650500_B28","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309534650500_B29","first-page":"41","article-title":"CTLA-4 gene polymorphism associated with Graves\u2019 disease in a Caucasian population","volume":"80","author":"Yanagawa","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122309534650500_B30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(99)01465-8","article-title":"Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy","volume":"354","author":"Vaidya","year":"1999","journal-title":"Lancet"},{"key":"2021122309534650500_B31","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1172\/JCI117289","article-title":"Retrobulbar T cells from patients with Graves\u2019 ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts","volume":"93","author":"Grubeck-Loebenstein","year":"1994","journal-title":"J Clin Invest"},{"key":"2021122309534650500_B32","first-page":"1232","article-title":"The thyrotropin receptors spread themselves around","volume":"79","author":"Davies","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122309534650500_B33","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2021122309534650500_B34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2021122309534650500_B35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"2021122309534650500_B36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"2021122309534650500_B37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"2021122309534650500_B38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122309534650500_B39","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309534650500_B40","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2021122309534650500_B41","doi-asserted-by":"crossref","first-page":"LBA100a","DOI":"10.1200\/jco.2015.33.18_suppl.lba100","article-title":"PD-1 blockade in tumors with mismatch repair deficiency","volume":"33","author":"Le","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B42","doi-asserted-by":"crossref","first-page":"4010a","DOI":"10.1200\/jco.2015.33.15_suppl.4010","article-title":"Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028","volume":"33","author":"Doi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B43","doi-asserted-by":"crossref","first-page":"LBA6008a","DOI":"10.1200\/jco.2015.33.18_suppl.lba6008","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort","volume":"33","author":"Seiwert","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B44","doi-asserted-by":"crossref","first-page":"5510a","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2021122309534650500_B46","doi-asserted-by":"crossref","first-page":"LBA101a","DOI":"10.1200\/jco.2015.33.18_suppl.lba101","article-title":"Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040","volume":"33","author":"El-Khoueiry","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B47","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II Trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B48","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B49","doi-asserted-by":"crossref","first-page":"9001a","DOI":"10.1200\/jco.2014.32.15_suppl.9001","article-title":"Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma","volume":"32","author":"Atkins","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B50","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122309534650500_B51","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B52","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122309534650500_B53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"15 suppl","key":"2021122309534650500_B54","doi-asserted-by":"crossref","first-page":"9050a","DOI":"10.1200\/jco.2015.33.15_suppl.9050","article-title":"Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001","volume":"33","author":"Robert","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B55","doi-asserted-by":"crossref","first-page":"9018a","DOI":"10.1200\/jco.2015.33.15_suppl.9018","article-title":"Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B56","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"2021122309534650500_B57","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7 suppl","key":"2021122309534650500_B58","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/jco.2015.33.7_suppl.296","article-title":"Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study","volume":"33","author":"O\u2019Donnell","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B59","doi-asserted-by":"crossref","first-page":"5570a","DOI":"10.1200\/jco.2015.33.15_suppl.5570","article-title":"Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B60","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1056\/NEJMra021194","article-title":"Thyroiditis","volume":"348","author":"Pearce","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122309534650500_B61","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B62","doi-asserted-by":"crossref","first-page":"9055a","DOI":"10.1200\/jco.2015.33.15_suppl.9055","article-title":"Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI)","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B63","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122309534650500_B64","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2021122309534650500_B65","doi-asserted-by":"crossref","first-page":"4047a","DOI":"10.1200\/jco.2015.33.15_suppl.4047","article-title":"A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer","volume":"33","author":"Yamada","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B66","doi-asserted-by":"crossref","first-page":"8010a","DOI":"10.1200\/jco.2015.33.15_suppl.8010","article-title":"Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR)","volume":"33","author":"Spira","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B67","doi-asserted-by":"crossref","first-page":"8032a","DOI":"10.1200\/jco.2015.33.15_suppl.8032","article-title":"Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Rizvi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or Monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2021122309534650500_B69","doi-asserted-by":"crossref","first-page":"3010a","DOI":"10.1200\/jco.2015.33.15_suppl.3010","article-title":"Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143","volume":"33","author":"Sampson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B70","doi-asserted-by":"crossref","first-page":"3009a","DOI":"10.1200\/jco.2015.33.15_suppl.3009","article-title":"Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study","volume":"33","author":"Atkins","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B71","doi-asserted-by":"crossref","first-page":"8011a","DOI":"10.1200\/jco.2015.33.15_suppl.8011","article-title":"Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D","volume":"33","author":"Patnaik","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B72","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","article-title":"Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management","volume":"37","author":"Kaehler","year":"2010","journal-title":"Semin Oncol"},{"key":"2021122309534650500_B73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3340\/jkns.2012.51.2.94","article-title":"A case of pituitary metastasis from breast cancer that presented as left visual disturbance","volume":"51","author":"Kim","year":"2012","journal-title":"J Korean Neurosurg Soc"},{"key":"2021122309534650500_B74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-0033-1355337","article-title":"Hypophysitis caused by ipilimumab in cancer patients: Hormone replacement or immunosuppressive therapy","volume":"121","author":"Lammert","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2021122309534650500_B75","volume-title":"European Medicines Agency: Keytruda. EPAR. 2015"},{"key":"2021122309534650500_B76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2021122309534650500_B77","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"15 suppl","key":"2021122309534650500_B78","doi-asserted-by":"crossref","first-page":"9037a","DOI":"10.1200\/jco.2009.27.15_suppl.9037","article-title":"Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity","volume":"27","author":"Amin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B79","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4158\/EP12280.GL","article-title":"Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association","volume":"18","author":"Garber","year":"2012","journal-title":"Endocr Pract"},{"key":"2021122309534650500_B80","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"issue":"15 suppl","key":"2021122309534650500_B81","doi-asserted-by":"crossref","first-page":"9004a","DOI":"10.1200\/jco.2015.33.15_suppl.9004","article-title":"Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study","volume":"33","author":"Hodi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B82","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MED.0b013e328338f608","article-title":"Adrenal insufficiency: Etiology, diagnosis and treatment","volume":"17","author":"Neary","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2021122309534650500_B83","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2265.1987.tb00780.x","article-title":"Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency","volume":"26","author":"H\u00e4gg","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122309534650500_B84","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.2003-030954","article-title":"Italian addison network study: Update of diagnostic criteria for the etiological classification of primary adrenal insufficiency","volume":"89","author":"Falorni","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122309534650500_B85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/jc.2003-030440","article-title":"Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women","volume":"89","author":"Purnell","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122309534650500_B86","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0300-595X(85)80084-0","article-title":"Adrenocortical insufficiency","volume":"14","author":"Burke","year":"1985","journal-title":"Clin Endocrinol Metab"},{"key":"2021122309534650500_B87","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"key":"2021122309534650500_B88","doi-asserted-by":"crossref","first-page":"e6333","DOI":"10.1136\/bmj.e6333","article-title":"How to avoid precipitating an acute adrenal crisis","volume":"345","author":"Wass","year":"2012","journal-title":"BMJ"},{"key":"2021122309534650500_B89","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.pcl.2005.07.006","article-title":"Type 1 diabetes mellitus: Etiology, presentation, and management","volume":"52","author":"Haller","year":"2005","journal-title":"Pediatr Clin North Am"},{"key":"2021122309534650500_B90","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.2337\/dc15-S012","article-title":"Microvascular complications and foot care. Sec. 9. In: Standards of Medical Care in Diabetes\u20142015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"issue":"15 suppl","key":"2021122309534650500_B91","doi-asserted-by":"crossref","first-page":"4505a","DOI":"10.1200\/jco.2013.31.15_suppl.4505","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC)","volume":"31","author":"Cho","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B92","doi-asserted-by":"crossref","first-page":"3000a","DOI":"10.1200\/jco.2013.31.15_suppl.3000","article-title":"A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","author":"Herbst","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B93","doi-asserted-by":"crossref","first-page":"9010a","DOI":"10.1200\/jco.2013.31.15_suppl.9010","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM)","volume":"31","author":"Hamid","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B94","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/annonc\/mdu205","article-title":"A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","volume":"25","author":"Aglietta","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309534650500_B95","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"2021122309534650500_B96","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122309534650500_B97","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B98","doi-asserted-by":"crossref","first-page":"4502a","DOI":"10.1200\/jco.2015.33.15_suppl.4502","article-title":"Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012","volume":"33","author":"Plimack","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B99","doi-asserted-by":"crossref","first-page":"8035a","DOI":"10.1200\/jco.2015.33.15_suppl.8035","article-title":"Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases","volume":"33","author":"Goldberg","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B100","doi-asserted-by":"crossref","first-page":"7502a","DOI":"10.1200\/jco.2015.33.15_suppl.7502","article-title":"Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028","volume":"33","author":"Ott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B101","doi-asserted-by":"crossref","first-page":"3023a","DOI":"10.1200\/jco.2015.33.15_suppl.3023","article-title":"Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"33","author":"Shitara","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B102","doi-asserted-by":"crossref","first-page":"8034a","DOI":"10.1200\/jco.2015.33.15_suppl.8034","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy","volume":"33","author":"Gulley","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7 suppl","key":"2021122309534650500_B103","doi-asserted-by":"crossref","first-page":"297a","DOI":"10.1200\/jco.2015.33.7_suppl.297","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B104","doi-asserted-by":"crossref","first-page":"8021a","DOI":"10.1200\/jco.2014.32.15_suppl.8021","article-title":"Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC","volume":"32","author":"Brahmer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B105","doi-asserted-by":"crossref","first-page":"3001a","DOI":"10.1200\/jco.2014.32.15_suppl.3001","article-title":"A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors","volume":"32","author":"Lutzky","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B106","doi-asserted-by":"crossref","first-page":"3002a","DOI":"10.1200\/jco.2014.32.15_suppl.3002","article-title":"Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody","volume":"32","author":"Segal","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B107","doi-asserted-by":"crossref","first-page":"3011a","DOI":"10.1200\/jco.2015.33.15_suppl.3011","article-title":"Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort","volume":"33","author":"Segal","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2021122309534650500_B109","doi-asserted-by":"crossref","first-page":"TPS4578a","DOI":"10.1200\/jco.2015.33.15_suppl.tps4578","article-title":"CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma","volume":"33","author":"Hammers","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B110","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2021122309534650500_B111","doi-asserted-by":"crossref","first-page":"3014a","DOI":"10.1200\/jco.2015.33.15_suppl.3014","article-title":"Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC","volume":"33","author":"Antonia","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B112","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/bjc.2014.126","article-title":"Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy","volume":"110","author":"Chiarion-Sileni","year":"2014","journal-title":"Br J Cancer"},{"key":"2021122309534650500_B113","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1756-9966-32-82","article-title":"Clinical experience with ipilimumab 10 mg\/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme","volume":"32","author":"Altomonte","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"key":"2021122309534650500_B114","first-page":"7","article-title":"Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma","volume":"13","author":"Weber","year":"2013","journal-title":"Cancer Immun"},{"key":"2021122309534650500_B115","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"issue":"15 suppl","key":"2021122309534650500_B116","doi-asserted-by":"crossref","first-page":"7503a","DOI":"10.1200\/jco.2015.33.15_suppl.7503","article-title":"Phase I\/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032","volume":"33","author":"Antonia","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B117","doi-asserted-by":"crossref","first-page":"8023a","DOI":"10.1200\/jco.2014.32.15_suppl.8023","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results","volume":"32","author":"Antonia","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309534650500_B118","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309534650500_B119","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309534650500_B120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B121","doi-asserted-by":"crossref","first-page":"3013a","DOI":"10.1200\/jco.2015.33.15_suppl.3013","article-title":"An ongoing phase IIIb\/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens","volume":"33","author":"Bauer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122309534650500_B122","doi-asserted-by":"crossref","first-page":"LBA109a","DOI":"10.1200\/jco.2015.33.18_suppl.lba109","article-title":"Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)","volume":"33","author":"Paz-Ares","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0509","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/804\/41875593\/oncolo_21_7_804.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/804\/41875593\/oncolo_21_7_804.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:39:11Z","timestamp":1640320751000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/7\/804\/6401426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,15]]},"references-count":122,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,6,15]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0509","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7,1]]},"published":{"date-parts":[[2016,6,15]]}}}